Drugs / Dupixent
Dupixent cost
dupilumab · Sanofi and Regeneron. Every official price for Dupixent, side by side, with who pays it.
Short answer
Sanofi lists Dupixent at $4,193.03 per carton (2 injections, which the maker defines as a monthly supply), as of January 2, 2026. Pharmacies paid an average of $2,017.88–$2,026.53 per pen or syringe (NADAC, Oct 21, 2026). At the FDA label dose of 300 mg every 2 weeks, after a first dose of 600 mg (an example), 4 weeks (2 × 300 mg pen) comes to $4,193.03 at the list price and $4,035.76 at the average pharmacy acquisition cost. In 2024, Medicare Part D spent $2.5 billion on Dupixent, an average of $4,009.96 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.125834
Source: FDA, Sanofi, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026
Dupixent: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per carton (2 injections, which the maker defines as a monthly supply) | $4,193.031 | Sanofi's price to wholesalers (WAC). Most people don't pay it directly. | January 2, 2026 |
| Pharmacy cost (NADAC) per month 4 weeks: 2 × 300 mg pen (FDA label dose, an example) | $4,035.762 | What pharmacies pay on average (CMS survey). Not a patient price. | Oct 21, 2026 |
On Medicare drug coverage: 5,492 of 5,492 Part D plans list Dupixent for 2027 (100%), and 100% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.14 By year and tier
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Dupixent (dupilumab) was first approved by the FDA on Mar 28, 2017, under application BLA761055.7
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $4,193.031 | Per carton (2 injections, which the maker defines as a monthly supply). The price the maker charges wholesalers; most people do not pay it directly. | January 2, 2026 (checked Oct 22, 2026) |
| Pharmacy acquisition cost (NADAC) Dupixent 200 mg/1.14 mL pen | $2,026.532 | Per pen or syringe ($1,777.65 per mL × 1.14 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Dupixent 200 mg/1.14 mL syringe | $2,022.612 | Per pen or syringe ($1,774.22 per mL × 1.14 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Dupixent 300 mg/2 mL pen | $2,017.882 | Per pen or syringe ($1,008.94 per mL × 2 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Dupixent 300 mg/2 mL syringe | $2,021.492 | Per pen or syringe ($1,010.74 per mL × 2 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below.
What Dupixent costs at the FDA label dose (example)
In the FDA label section "Atopic Dermatitis Dosage in Adults", the dose is 300 mg every 2 weeks, after a first dose of 600 mg.56 We use it only to show the math with official prices. It is an example, not a dosing recommendation: your dose is your doctor's decision, and other uses on the label have other doses.
300 mg pen prices: list price January 2, 2026; NADAC effective Oct 21, 2026. FDA label version 60 (Apr 22, 2026).
| Period | At list price | At pharmacy acquisition cost (NADAC) |
|---|---|---|
| 4 weeks 2 × 300 mg pen: 1 pen every 2 weeks × 4 weeks | $4,193.031 | $4,035.762 |
| A year (52 weeks) 26 × 300 mg pen: 1 pen every 2 weeks × 52 weeks; the extra pen in the 600 mg first dose is not counted | $54,509.391 | $52,464.882 |
How we count: list price $4,193.03 per carton (2 injections, which the maker defines as a monthly supply), divided by 2 and multiplied by the count; NADAC $2,017.88 per 300 mg pen (Dupixent 300 mg/2 mL pen) times the count. None of these is what you pay at the counter: the list price is what the maker charges wholesalers and NADAC is what pharmacies pay to buy the drug.
What Medicare spent on Dupixent in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,9 and it does not reflect manufacturers' rebates.10 CMS lists Dupixent in 2 rows; together they come to $2.5 billion over 621,396 prescription fills, $4,009.96 per fill.
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Dupixent Pen | $1.8 billion8 | 450,526 | 65,541 | $4,005.6611 | $27,534.7312 |
| Dupixent Syringe | $687.1 million8 | 170,870 | 22,833 | $4,021.2911 | $30,093.2212 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
How many Medicare Part D plans list Dupixent
Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.
| Plan year | Plans that list it | Prior auth. | Step therapy | Quantity limit | Lowest tier (plans) |
|---|---|---|---|---|---|
| 2026 | 5,496 of 5,49613 100% | 5,496 | 0 | 5,122 | tier 1: 161 · tier 2: 2 · tier 4: 50 · tier 5: 5,283 |
| 2027 | 5,492 of 5,49214 100% | 5,492 | 0 | 5,207 | tier 1: 123 · tier 2: 1 · tier 4: 46 · tier 5: 5,322 |
Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.
Dupixent pharmacy cost over 2026 (NADAC)
Every NADAC rate in our archived copy of CMS's 2026 NADAC file (weekly files Jun 3, 2026 to Oct 21, 2026). NADAC is what pharmacies pay on average, not a patient price.
| Product (NADAC description) | Effective dates | First rate | Latest rate | Change |
|---|---|---|---|---|
| DUPIXENT 200 MG/1.14 ML PEN | 2026-05-20, 2026-06-17, 2026-07-22, 2026-08-19, 2026-09-23, 2026-10-21 | $2,028.4815 | $2,026.53 | -0.1% |
| DUPIXENT 200 MG/1.14 ML SYRING | 2026-05-20, 2026-06-17, 2026-07-22, 2026-08-19, 2026-09-23, 2026-10-21 | $2,015.5615 | $2,022.61 | +0.35% |
| DUPIXENT 300 MG/2 ML PEN | 2026-05-20, 2026-06-17, 2026-07-22, 2026-08-19, 2026-09-23, 2026-10-21 | $2,018.0815 | $2,017.88 | -0.01% |
| DUPIXENT 300 MG/2 ML SYRINGE | 2026-05-20, 2026-06-17, 2026-07-22, 2026-08-19, 2026-09-23, 2026-10-21 | $2,021.0415 | $2,021.49 | +0.02% |
With Medicare
- What you pay depends on your Part D plan. The rules that apply to every Part D drug, from the deductible to the $2,400 out-of-pocket limit in 2027, Extra Help and the Medicare Prescription Payment Plan, are on one page: Part D costs · payment plan. Free one-on-one help: a SHIP counselor or 1-800-MEDICARE.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Sanofi: DUPIXENT frequently asked questions (cost). We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (15)
“The list price of DUPIXENT is $4,193.03 USD per carton ... List price is also referred to as wholesale acquisition cost or WAC ... A monthly supply/carton of DUPIXENT (300 mg or 200 mg) is defined as 2 injections per month. List price as of 1/2/2026.”
Sanofi: Dupixent pricing (entered by hand) · as of Oct 22, 2026- data.medicaid.gov: NADAC (National Average Drug Acquisition Cost) 2026 · as of Oct 23, 2026
“Out-of-pocket limit Yearly $2,100 (in 2026).”
Medicare.gov: Medicare costs · as of Oct 23, 2026“Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (Table V-6) · as of Oct 23, 2026“Recommended dosage is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”
FDA label (DailyMed): Dupixent, version 60 · as of Nov 15, 2026“Pack of 2 pens”
FDA label (DailyMed): Dupixent, version 60 · as of Nov 15, 2026“BLA761055 ORIG-1 approved 20170328”
FDA (Drugs@FDA via openFDA): BLA761055 · as of Nov 15, 2026“Dupixent Pen: Tot_Spndng_2024 1804653435.9, Tot_Clms_2024 450526, Tot_Benes_2024 65541; Dupixent Syringe: Tot_Spndng_2024 687118572.15, Tot_Clms_2024 170870, Tot_Benes_2024 22833”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026- CMS: 2026_20260916.zip (Part D formulary file for 2026 plans, published 2026-09-23) · as of Nov 15, 2026
- CMS: 2027_20261008.zip (Part D formulary file for 2027 plans, published 2026-10-15) · as of Nov 15, 2026